Bing brings more than 20 years’ experience in the biopharmaceutical industry, with a track record of leading successful discovery and development of multiple biotherapeutics. Most recently, Bing was Senior Vice President, Head of Respiratory, Inflammation, Autoimmune iMED, MedImmune, AstraZeneca. During his tenure at MedImmune, he played key leadership roles in the development and approval of three novel biologics for autoimmune, respiratory, and immune-oncology indications respectively. Bing was also Senior Vice President, Head of Immuno-Oncology Franchise, AstraZeneca. In addition, he was the CEO for WuXi-MedImmune Joint Venture. Bing joined MedImmune in 2010 from Genentech, where he was the Head of PTL for Immunology, Infectious Diseases, Neuroscience, and Metabolic Disease. He was Vice President and Head of Research for Tanox, before it was acquired by Genentech in 2007. Bing also held multiple positions with increasing responsibilities at Aventis and Amgen. Bing is on the Board of Directors for NexImmune. Bing received his Ph.D in Microbiology and Immunology from the University of Iowa, followed by postdoctoral work at Immunex.
At Viela Bio, Mitchell is responsible for leading corporate financing, financial operations, treasury, investor relations, public relations and developing corporate strategy. Mitchell brings more than 15 years of finance experience to Viela Bio. Most recently, Mitchell was the Director of Investor Relations for AstraZeneca, North America. Prior to joining AstraZeneca, Mitchell was at Genentech-Roche in roles of increasing responsibility, including BioOncology Commercial Finance, R&D Finance, and Mergers & Acquisitions. Mitchell have received Executive Certifications from Stanford University, University of California (Haas), and University of Pennsylvania (Wharton). Mitchell earned his BSc, MSc and MBA (Rotman School of Management) from the University Toronto.
Jorn brings more than two decades of experience in research and development in the inflammation and autoimmune therapeutic areas. Most recently, Jorn was Vice President, Clinical, MedImmune, where he headed the clinical functions of Respiratory, Inflammation, Autoimmune, Cardiovascular, Metabolic disease, and Infectious disease. Jorn joined MedImmune in 2011 from Genentech, where he was a Senior Medical Director for the Inflammation and Autoimmune assets. Jorn started his career as a Medical Director for Amgen. He received his medical degree from the University of Cologne in Germany and a Ph.D. in immunology from Cornell Medical School/Hospital for Special Surgery, followed by residency at New York Hospital and Rheumatology fellowship at the Hospital for Special Surgery.
Soraya brings more than two decades of experience in Project Leadership and Regulatory affairs. Most recently, Soraya was a Senior Director, Project Development Team Leader at MedImmune, responsible for the development of inebilizumab, prezalumab, and MEDI0700. Before she joined MedImmune in 2011, Soraya was a Director of Regulatory Policy at Novartis, and had increasing responsibilities in the R&D organization at Novartis. Soraya started her career as a Reviewer at the Food and Drug Administration (FDA). Soraya received her Ph.D. in Pharmaceutics from the University of Washington.
Maureen comes to Viela with over 25 years of biotech experience, specializing in orphan and ultra-orphan drug launches. Most recently in the role of Head of U.S. Market Access for Amicus Therapeutics, she developed strategies and managed commercial activities for market readiness, new product launch, targeted distribution and specialty pharmacies, reimbursement, patient access and patient support services. As Senior Director, Market Access and Key Accounts for NPS Pharma, she successfully launched two first-in-class ultra-orphan products in three years. In addition, Maureen served for 9 years as Managed Markets Director at Genzyme. She was also a Sales leader at Genentech, and has a BSN from the University of Toledo.
Bill brings more than 20 years of commercial experience to Viela. Most recently, Bill was a Director for AstraZeneca leading the worldwide commercial strategy for anifrolumab in systemic lupus erythematosus. Prior to joining AstraZeneca, Bill spent 15 years at Boehringer-Ingelheim in roles of increasing responsibilities including leading the launches in respiratory, cardiovascular and oncology. Bill started his pharmaceutical career at Merck and received his MBA from the Fuqua School of Business at Duke University.
Aaron brings 15 years’ experiences in biopharmaceutical business, and research and development, with both breadth and depth. At Viela Bio, he manages Quality, IT, Business Development, Procurement and Contracts functions. Most recently, Aaron was the MedImmune China Lead, leading company R&D initiatives for China, and he was also a Director of Business Development, with MedImmune’s BioPharmaceutical Development and Partnering groups respectively. Before he joined MedImmune in 2014, Aaron was with McKinsey & Co, SR One and held multiple roles in R&D with increasing responsibilities with Schering-Plough and Abbott Labs. Aaron received his MBA with honors in Finance and Healthcare Management from the Wharton School at the University of Pennsylvania and a Ph.D. in Pharmaceutics from the University of Washington, during which he was an Eli Lilly Fellow.
Kate has more than two decades of diverse experience in Human Resources. Kate’s deep experience in talent acquisition, succession strategy, workforce planning, performance coaching and organizational change management will support and enhance Viela’s capabilities and organizational infrastructure. For the past decade, Kate has held a variety of HR roles with increasing responsibilities, primarily with MedImmune and AstraZeneca. Most recently, Kate was a Global Director at AstraZeneca where she supported multiple functions within the biologics and small molecule teams. Prior to entering a global role, she was Director of HR, Training and Communications at the Frederick Manufacturing Facility, where she developed and executed a strategic workforce plan that grew staff from approximately 150 to 650 employees. Kate served in HR roles at Fugro EarthData, a global oil and gas company, and Pearson Education. Kate holds a BA in History from the University of North Carolina at Wilmington.
Yang brings more than 17 years’ experience in biopharmaceutical process development and commercialization. At Viela Bio, she oversees all aspects of process development, manufacturing, and supply of clinical and commercial products across portfolio. Most recently, Yang was Senior Director, Analytical Sciences at Biopharmaceutical Development, MedImmune. Made key contributions to the BLA/MAA approval of three novel biologics. Yang also held Director, Purification Process Sciences at MedImmune. Led development of scalable downstream process for multiple complex novel molecules. Established CMC Team Leader with proven success record leading both early and late stage CMC teams, including WuXi-MedImmune Joint Venture CMC Team. Prior to join MedImmune in 2009, Yang worked at Amgen and Pfizer with increasing responsibilities in process development, characterization, technology transfer, commercial manufacturing support and post approval changes. Yang received her Ph.D in Biochemistry from University of Virginia, followed by Postdoctoral Research at Department of Cellular and Molecular Pharmacology at University of California, San Francisco.